Precision Analgesia for Cardiac Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Analgesia, Cardiac Surgery. Basic parameters: 60 years — 110 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Precision Perioperative Methadone Use in Adult Cardiac Surgical Patients to Reduce Opioid Use Adverse Effects While Improving Analgesia and Outcomes
Overview
The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research. This research focuses on two of the most commonly used oral opioid analgesics, oxycodone, and methadone in elderly adults undergoing cardiac surgery.
Detailed description
Cardiac surgery patients often experience significant acute postoperative pain, and untreated or undertreated pain has consequences. Each year, 900,000 painful cardiac surgeries occur in the US alone. Pain associated with cardiac surgery results from surgical incision, sternal retraction, internal mammary artery harvesting, saphenous vein removal, placement of mediastinal and chest drains, sternal wires, and release of pro-inflammatory mediators after tissue injury. One study reported that 49%, 62%, and 78% of patients reported severe pain at rest, movement, and coughing, respectively after coronary artery bypass surgery (CABG). Another study showed that 61.4% of patients undergoing cardiac surgery reported moderate to severe pain. Inadequate pain treatment is common in cardiac surgery due to health care providers' fears of causing cardiorespiratory compromise. Poor pain control can trigger sympathoadrenal responses leading to cardiac arrhythmias and myocardial ischemia, restrict mobility to cause venous thrombosis, impair clearance of secretions leading to pulmonary complications such as atelectasis and pneumonia, decrease patient satisfaction and predispose to the development of chronic, persistent surgical pain (CPSP).
Improving clinical practice by shifting paradigms: Our research is transformative and will evolve current reactive clinical practice towards proactive precision methods based on genetic risks for surgical pain and ORADE in elderly vulnerable population. This is the first effort to move in the direction of personalizing perioperative opioid use with precise dosing to improve safety and efficacy in cardiac surgery. Preoperative genotyping-based clinical decisions are expected to support clinical implementation in real-world settings. Importantly, investigators will be able to reach beyond the current best-in-class outcomes with precision multi-dose methadone analgesia based on proactive genetic risk identification to maximize safety and efficacy of opioids in all cardiac surgical patients and positively impact socio-economic outcomes in the future. By addressing these critical barriers, this research will help physicians identify patients at risk and improve the safety and efficacy of opioids and surgical pain management while preventing OD, misuse, overdose, and deaths.
Primary outcome measures
- Determine Genetic Factors - Opioid Related Adverse Events (RD) [Time frame: Immediately post-surgery during hospital stay]
- Determine Genetic Factors - Opioid Related Adverse Events (PONV) [Time frame: Immediately post-surgery during hospital stay]
- Determine Genetic Factors - Opioid Related Adverse Events (Excessive Sedation) [Time frame: Immediately post-surgery during hospital stay]
- Determine Genetic Factors - Uncontrolled severe pain [Time frame: Immediately post-surgery during hospital stay]
Secondary outcome measures (3)
- Opioid use post-operatively [Time frame: Post-operative Day 5 to 6-months post-operative]
- Patient-Reported Outcomes Measurement Information System [Time frame: Post-operative Day 5 to 6-months post-operative]
- Incidence of Chronic Persistent Surgical Pain (CPSP) [Time frame: Post-operative Day 5 to 6-months post-operative]
Eligibility criteria
Inclusion criteria
- Elderly cardiac surgical patients over 60 years of age
Exclusion criteria
- Methadone allergy
- Morbid obesity (BMI >40kg/cm2)
- Severe sleep apnea
- Severe pulmonary disease requiring oxygen therapy
- Preoperative mechanical circulatory support
- Emergency surgery
- Liver disease (liver enzymes more than two times normal)
- End-stage renal disease requiring dialysis
- Serum creatinine more than 2.0mg
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- UPMC Presbyterian Hospital — Pittsburgh
Identifiers
NCT: NCT05612399 · STUDY22060101